Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

/ul>
  • Improvements in diastolic blood pressure (DBP) with empagliflozin versus placebo:
    • In patients with mild renal impairment, DBP decreased by 1.4 mmHg (p=0.006) and
      2.2 mmHg (p<0.001) for empagliflozin 10 mg and 25 mg, respectively, while it increased by 1.1 mmHg for placebo
    • In patients with moderate renal impairment, DBP decreased by 1.7 mmHg (p=0.020) for empagliflozin 25 mg and increased by 0.2 mmHg for placebo.1
  • The percentage of people with mild renal impairment who reported drug-related AEs at 52 weeks were 37.8 percent, empagliflozin 10 mg; 41.2 percent, empagliflozin 25 mg; and 32.6 percent, placebo. Drug-related AEs at 52 weeks in patients with moderate renal impairment were reported by 27.3 percent, empagliflozin 25 mg; and 24.1 percent, placebo. Observed AEs included hypoglycemia, events consistent with urinary tract infection, events consistent with genital infection, events consistent with volume depletion, and events consistent with bone fracture.

    About the study
    The 52-week randomized, double-blind, placebo-controlled trial investigated the safety and efficacy of empagliflozin as add-on to existing therapy in people with type 2 diabetes mellitus and renal impairment.1 Patients with mild renal impairment received empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Patients with moderate or severe renal impairment received empagliflozin 25 mg or placebo. The primary endpoint was change from baseline in HbA1c at week 24. Exploratory endpoints included changes from baseline in FPG, weight and BP at week 24.1

    About the Empagliflozin Phase III Clinical Trial Program
    Empagliflozin is being investigated in adults with T2D in a phase III clinical trial program that has enrolled more than 14,500 people. In total, this program comprises more than 10 multinational clinical trials, including a l
    '/>"/>

    SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
    2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
    3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
    4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
    5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
    6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
    7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
    8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
    9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... 2014 Research and Markets  has announced ... Market Research Report 2014" report to their offering. ... Report 2014 presents comprehensive data on paracetamol (acetaminophen) markets ... Asia , North America ... (acetaminophen) description, covers its application areas and related patterns. ...
    (Date:9/15/2014)... , Sept. 15, 2014 Sysmex America, ... information systems technology, announced today an amended distributorship ... is for Sysmex reagents, controls and instruments including ... ™ , Sysmex XP-300™, XT-Series and XN-Series ... is effective immediately and continues until August 31, ...
    (Date:9/15/2014)... , Sept. 15, 2014  Mariel Therapeutics, Inc., ... Protein-7 and its application in Osteoarthritis (OA) and Chronic ... experts to its newly formed scientific advisory board. The ... and scientific resource to the company as it continues ... "We are honored to have such leading experts in ...
    Breaking Medicine Technology:Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 2Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 4
    ... Mass., Aug. 25, 2011 Caliper Life Sciences, ... that its presentation at the Stifel Nicolaus Healthcare ... at 11:30 a.m. EDT.  Kevin Hrusovsky, President and ... on the company,s business. The live webcast can ...
    ... Aug. 25, 2011 PDI, Inc. (Nasdaq: ... promotional and commercialization services to health care companies, today ... Top 10 pharmaceutical company has been renewed for an ... PDI,s Shared Sales team beginning in September 2011 through ...
    Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2
    (Date:9/16/2014)... Dr. Eric Millstein of Beverly Hills is ... a specialty website devoted to the diagnosis and treatment ... lover and athlete, Dr. Millstein focuses on offering patients ... to maintain active, healthy lifestyles. , “We’re very excited ... specifically to ACL injuries and treatment,” says ...
    (Date:9/16/2014)... 16, 2014 Lambda Solutions, a leader in ... is excited to welcome Stewart Rogers on board ... Executive at Lambda Solutions comments, “Product leadership will take Lambda ... to do so. Learning and talent management is at a ... help clinical learning and talent development in the past ten ...
    (Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Online ... be offering $0 shipping on all kettlebell purchases in ... easy for customers to get started with this effective ... the Crossfit movement. The online store carries a variety ... and free weekly workouts guides. , “We’ve ...
    (Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
    (Date:9/16/2014)... 2014 Dakota Software , ... (EHS) and Sustainability management software, today announced that ... versatile software platform, MobileWorkflows, at their Annual Users ... MobileWorkflows allow for on-the-go access to Dakota’s enterprise-level ... Responsive Web Design, MobileWorkflows feature a streamlined user ...
    Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:Mobile EHS Compliance Tools the Focus of Dakota Software’s 2014 Users Conference 2
    ... In the report titled Millennium Ecosystem Assessment, scientists have said ... having a detrimental effect to human health and may cause ... malaria and cholera are threatening to cause a major outbreak ... beneficial factors of the eco system are being used in ...
    ... published in American Journal of Public Health, researchers had been ... causes of asthma in children by interventions due to health ... children in the age group of 4 to 12 yrs ... period of one year during which community health workers used ...
    ... US and Canadian scientists, consuming food with high glycemic index ... ,The study, which had spanned 16.6 years and observed ... that the risk is much significant for women who are ... often found in foods that have simple carbohydrates and sugars ...
    ... a data comprising of 5461 girls between 11 to 15 ... these girls more prone to stress fractures. ,The study ... physical activity, which often lasts for 16 or more hours ... of having a stress fracture than the girls doing physical ...
    ... market watchdog Food and Drug Administration had announced a series ... class of non-steroidal anti-inflammatory drugs that are sold with or ... of the drug Bextra (valdecoxib) from Pfizer, Inc. ... FDA had reports that the overall risk associated with the ...
    ... have completed the second phase of testing of the ... of cervical cancers and 90% of genital warts. ... for 36 months and regularly had gynecological examination, cervicovaginal ... serum antibodies to HPV. , ,The results showed ...
    Cached Medicine News:
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: